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ABSTRACT
Tuberculosis (TB) has surpassed HIV to become the leading infectious killer of 
adults globally, causing almost 2 million deaths annually.1  Although this airborne 
disease has been treatable since 1948, global rates of TB have dropped less than two 
percent per year; an estimated 10 million incident cases continue to occur annually, 
including one million in children.1,2  While transmission of active disease is an important 
driver of the epidemic, the seedbed that feeds the epidemic is the more than two billion 
people estimated to have TB infection, five to ten percent of whom will progress to 
active disease during their lifetime.3  While any successful strategy aimed at TB 
elimination needs to address this reservoir of TB infection worldwide, much remains to 
be understood about host and pathogen factors that can be used to identify increased 
risk for progression to disease, and intervened upon to prevent progression from 
occurring.4
The Division of AIDS of the National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, USA, and the Harvard Medical School Center for Global 
Health Delivery–Dubai convened a group of scientists and stakeholders on September 
28 and 29, 2017, to address knowledge gaps that affect our ability to rapidly find and 
treat individuals infected with Mycobacterium tuberculosis who are most likely to 
progress to active disease.  The meeting identified a number of efforts underway to 
address this important gap in the collective ability to stop the global TB epidemic.  Here, 
we review and outline the priority areas for research, diagnosis and treatment of TB 
infection that emerged from the meeting (Table 1), building on recent reviews in this 
area.5,6,7  
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Understanding the spectrum of TB infection and disease: a critical first step
Although epidemiological data from the late 1950s—and a number of randomized 
controlled trials since then—demonstrate the importance of treating TB infection before 
it becomes clinically apparent (preventive therapy for so-called “latent” TB),8,9,10,11,12 
very little is known about the spectrum of clinical states between asymptomatic infection 
and clinically apparent disease.  It is becoming increasingly clear that conventional 
conceptions of TB as “latent” versus “active” are overly simplistic, and neither 
adequately reflect host immunology nor microbial pathogenesis.13,14,15  Indeed, there is 
now increased appreciation that clinically apparent “TB disease” is assuredly preceded 
by a period of incipient TB—an asymptomatic phase that can been characterized by an 
evolving blood-based host RNA signature.16 These observations confirm that the 
previous classification of “latent” infection is imperfect and limited by the characteristics 
of available diagnostic tests.17  Moreover, it is hypothesized that some exposed 
individuals can mount effective immune responses that eradicate all viable bacilli, a 
phenotype distinct from persons in whom immune responses can only contain the 
infection, thereby harbouring populations of bacilli that intermittently replicate in 
macrophages, granulomata and other tissues.4   Whether the newer terminology of 
“incipient” disease indicates early active TB that inevitably progresses to clinically 
apparent disease, or whether it is more of a dynamic state that reflects ongoing host-
pathogen interactions, remain unknown. In addition, the definitions and pathophysiology 
of a pre-incipient state is also unknown.  Being able to characterize and identify the full 
spectrum of “latency”, including the dynamics of microbial and host interplay and the 
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role this relationship has in developing disease is a critical component to addressing the 
TB epidemic (Figure 1).  
It has long been hypothesized that sub-clinical TB infection is characterized by a 
population of M. tuberculosis in a dormant or metabolically quiescent state.18,19  Rather, 
recent data on changes in host immunity during TB infection and the efficacy of 
treatment for TB infection point towards a population of organisms that have substantive 
metabolic activity.14,20  The true nature of bacterial metabolism, and associated 
vulnerability to anti-tubercular drugs, remains a critical knowledge gap that has been 
difficult to study in humans due to the inability to meaningfully sample bacteria prior to 
TB disease progression.19 To address this, in vitro, ex vivo and in vivo models have 
been established to study various aspects of non-replicating persistence in 
mycobacteria. Passage of M. tuberculosis through these models reveals a dynamic and 
complex pathogen response to the immune stresses imposed during infection.19 For 
example, in vitro models that simulate the non-replicative state demonstrate that carbon 
metabolism is extensively remodelled to accommodate for a reduction in simple 
glycolytic substrates and an increase in the availability of fatty acids and host derived 
cholesterol.21,22,23,24  Similarly, nitrogen metabolism is rewired to respond to increasing 
availability of nitrate, a by-product of host-derived reactive nitrogen stress.25,26 In vitro 
models and infection studies in animals show specific pathogen metabolic adaptations 
that address the reduced levels of oxygen present in the TB granuloma.19,27,28,29 
Collectively, data from these models of non-replicating mycobacterial persistence 
suggest that the bacteria are not metabolically quiescent. While this finding may provide 
an explanation for the effectiveness of preventative therapy with agents that target 
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active cellular processes given over an extended time-frame (e.g. isoniazid and 
rifampin),4,8,9,10,11,12 it is not yet clear how much these in vitro models correspond to 
mycobacterial activity in humans.
There are many unanswered questions regarding the ability of tubercle bacteria 
to survive in an immune-active host.  Gaps exist in understanding where bacteria are 
located during the early stages of TB infection and whether different locations and 
environments affect bacterial behaviour and treatment response.19  How similar is the 
bacterial metabolism along the spectrum between infection and disease?  If there are 
differences, how do we define vulnerable drug targets for TB infection?  Would 
recognition of bacterial behaviour during early conditions allow us to define new 
growth/media conditions for diagnosis?  These are all critical areas of inquiry. 
The interplay between bacterial and host genetics and the subsequent 
combinatorial effect on host immune response during infection is another important area 
of research. First, we know that M. tuberculosis can interact with a large repertoire of 
innate host receptors that shape the immune response and outcome of infection and 
progression to disease.30 For example, eicosanoid generation, considered as a host 
protective response to mycobacteria, is regulated by leukotriene A(4) hydrolase 
(LTA4H). In tuberculous meningitis, a genetic polymorphism in LTA4H is associated 
with both inflammation and responsiveness to adjunctive anti-inflammatory therapies.31  
Second, immune responses appear to also be influenced by M. tuberculosis strain 
diversity.  Mycobacterium tuberculosis Complex (MTBC) comprises seven human 
adapted lineages and studies have reported that genotypic diversity is associated with 
differences in host immune responses.32,33,34  That the interaction between host 
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polymorphisms and TB strain variation may dictate the outcome of infection is illustrated 
in a study that showed that the association of SNP TLR2 T597C with risk of TB 
meningitis is strongest among those infected with the Beijing lineage.35  
Overall, it is plausible that the spectrum of infection is influenced by a 
combinatorial effect of both host and bacterial genotypes.  A better understanding of the 
nuances of host-pathogen dynamics during different M. tuberculosis infection states and 
with M. tuberculosis genetic diversity would contribute to developing protective vaccines 
for TB infection and therapeutic vaccines for treatment. It would also help to identify 
biomarkers of pathogen clearance and of progression to TB, and advance our 
understanding of host innate and adaptive immunity to M. tuberculosis.  This is critical 
for eradicating persistent infection, preventing reactivation of TB infection, shortening 
TB infection treatment and/or preventing re-infection. 
Diagnosing TB Infection and Progression to Disease
Another major gap in addressing TB infection has been the inability to 
differentiate between asymptomatic individuals harboring viable persistent bacteria 
versus those that have cleared the infection.  This is highly relevant for the accurate 
identification of infected individuals that are at greatest risk for progressing to TB 
disease. Whereas persons with positive interferon gamma release assays specific for 
TB antigens are at increased risk of progressing to clinically apparent disease, the 
number needed to treat to prevent a single active case can range as high as from 111 
to 314 (depending on setting and the patient’s risk for progression), an observation that 
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has dampened enthusiasm for universal treatment of TB infection.36 While recent 
studies have identified host biomarkers and transcriptional profiles associated with 
active TB and signatures associated with TB disease risk,37,38,39 signatures that 
distinguish persistent TB infection from cleared infection have not been identified. 
Moreover, the effect on these signatures by co-infection with HIV or helminths, or co-
morbidities such as diabetes, is not known. 
Overall, there are substantial problems with current definitions of infection since 
they are generally inferred from surrogate assays that measure the metabolic, 
transcriptomic or bimodal immunologic response of the host to an encounter with M. 
tuberculosis.  The extent to which surrogate markers reflect characteristics of 
infection—versus “conversion”—remains unknown. It is recognized that individuals post-
conversion exhibit both increased risk for progression and heterogeneity in timing of 
progression.  Exposed individuals who do not convert may represent a “resistance to 
infection” phenotype. Genetic mapping efforts of M. tuberculosis infection offer 
particularly powerful approaches for identifying loci that confer resistance to infection or 
that control progression from conversion to clinical disease.  These efforts may also be 
useful in fine-tuning surrogate markers to improve the accuracy of prediction of 
progression to clinical disease.  For example, transcriptomic signatures have been 
identified that provide a correlate of risk for progression from conversion to disease with 
relatively good accuracy.40 By including genetic markers that impact on transcript levels, 
so called eQTL loci, it may be possible to further improve the accuracy of these 
signatures.  Much needs to be done in this area.  
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Despite the checkered history of serologic assays in TB, more refined 
understanding of the antigen binding (Fab) and constant (Fc) domains would support 
accurate antibody-based diagnostics. Most antibody work has focused on the Fab 
domain given the specificity of association with microbial antigens. Unfortunately, this 
approach has thus far given rise to commercial serological tests with poor sensitivity 
and specificity for TB infection and disease.  However, it is well understood that 
immunogenic microbial antigens are not just proteins but also lipids and carbohydrates. 
Recent studies have shown that the “constant” Fc domain is actually diverse, capturing 
a plethora of host-associated processes.41 More specifically, isotypes (n=5), subclasses 
(n=6), and post translational modifications such as glycosylation (n=at least 36) are 
dynamic throughout the course of disease, reflecting the host immune responses.42 
These Fc features, specifically glycosylation, have been successfully used in oncology 
to functionally enhance monoclonal antibody therapeutics, in rheumatology to provide 
more predictive and granular biomarkers, and in HIV diagnostics.43,44,45 Overall, these 
important advances in our understanding of the role of antibodies suggest that further 
research is essential46. 
The measurement of other aspects of cellular immunity to mycobacterial infection 
may provide signals that discern TB infection from active disease, and hence might be 
used to define those with subclinical TB.  As M. tuberculosis is an intracellular 
pathogen, CD8+ T-cells are uniquely poised to sample the intracellular environment.  
The prevalence of M. tuberculosis-specific CD8+ T-cells is associated with surrogates of 
bacterial burden such as sputum-smear positivity and is inversely correlated with 
treatment.  Innate T-cells, such as invariant natural killer cells and mucosal associated 
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invariant T-cells, are diminished in the circulation of individuals with M. tuberculosis, 
possibly reflecting their movement to the site of active infection.  Increased numbers of 
myeloid derived suppressor cells in blood of recently exposed individuals and in TB and 
increased numbers at the site of disease in pleural TB have been found, whereas these 
numbers normalize after prolonged asymptomatic infection and after successful TB 
treatment. These cells suppress innate and adaptive immune responses against TB.47,48  
Expression of immune activation markers such as CD38 and HLA-DR and intracellular 
proliferation markers such as Ki-67, on Mtb-apecific CD4 T cells have been shown to 
accurately discriminate between active TB disease and TB infection, suggesting that 
antigen-specific T cell phenotypes can be useful as biomarkers of TB disease.49 Finally, 
the measurement of the functional status of M. tuberculosis-specific CD4+ T-cells—
using either IL-2 production or cellular activation—has been demonstrated to discern TB 
from TB infection.50  In summary, understanding better the host response to infection 
with M. tuberculosis has the potential to predict those at risk for progression, add 
specificity to RNA signatures, and guide therapy.  
As high TB incidence areas are often characterized by high sensitization rates to 
M. tuberculosis antigens (i.e. TST or IGRA positivity), these tests are of limited value in 
selecting healthy individuals for targeted preventative treatment.51 Recent publications 
have highlighted a new approach using gene signatures to predict future progression to 
clinically active disease in people who are apparently healthy at the time of 
testing.40,52,53 The Adolescent Cohort Study, reported the generation of a risk signature 
from whole blood RNA sequencing followed by validation through multiplex quantitative 
real-time PCR in adolescents without a known exposure episode from a high TB 
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incident community. The expression of 16 mRNA transcripts constituted a correlate of 
risk (CoR) for active TB disease and was validated in a cohort of recent household 
contacts of active TB cases from South Africa and The Gambia (the GC6-74 study).38  
The CoR progression in the adolescent cohort was similar to CoR regression towards a 
control state in an independent TB treatment cohort that was recently reported from 
South Africa.54 Subsequent further analysis of the GC6-74 cohort showed similar 
promising predictive performance across household contacts from multiple sites, 
suggesting that predictive signatures are indicative of incipient disease up to two years 
prior to the development of symptoms, and that signatures that perform reasonably well 
across different geographical areas should best be developed from data sets that 
include samples from multiple locations55. Such signatures are now being tested 
prospectively in clinical trials of biomarker-driven targeted preventative treatment.40Error! 
Bookmark not defined.
Newer discovery platforms, like next-generation biological mass spectrometry, 
coupled with methods for enhancing sensitivity such as exosome enrichment, are being 
evaluated for the detection of pathogen-specific markers across the spectrum of TB 
infection to disease.56,57 Pathogen-specific diagnostics would provide a valuable 
alternative to surrogate marker approaches and be able to discern true “infection” in M. 
tuberculosis exposed patients from immunologic “conversion” after exposure.  
Lastly, the fundamental challenge of how to optimize the evaluation of 
diagnostics for TB infection, for which there is no gold standard, needs to be addressed.  
Historically, active TB disease cohorts have been used, but the severe immunologic and 
pathogen features of this state are recognized as poorly reflective of the pre-disease, 
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infection state. Proxies for infection (e.g. based on TST or IGRA results) are also used 
in studies, including proposed new cut-offs for defining positive results,58 and these can 
be further enhanced by determining whether a novel biomarker or diagnostic test 
separates the study population into two groups of size consistent with the known 
epidemiology of TB infection: the majority (80-95%) with stable TB infection and a 
minority (5-20%) identified as being at-risk (i.e., unstable TB infection or sub-clinical 
TB). This approach still has risk in terms of misclassification, but candidate biomarkers 
that achieve this goal could then be advanced to Phase 2 studies that assess changes 
in the candidate biomarker levels with treatment of TB infection.  In the absence of a 
reference standard, assessing for treatment response is also a reasonable approach 
and is supported by prior studies demonstrating that gene expression is similar among 
patients who have completed treatment for TB disease and controls with TB infection.59 
Such Phase 1 and 2 studies require smaller sample sizes and shorter follow-up as 
compared to large epidemiologic cohorts, and could help identify potential candidate 
biomarkers or tests to advance to clinical impact studies that assess TB incidence.
Innovations in Treatment of Infection
Recently completed trials of duration shortening regimens for drug-susceptible 
TB infection have confirmed the importance of treating TB infection and provided viable 
alternatives to the conventional nine months of isoniazid (9H) used since the 
1960’s.8,9,10,11,12 Several randomized controlled trials have shown that a new 
combination regimen of isoniazid (INH) and rifapentine (RPT) administered weekly for 
12 weeks as directly observed therapy (DOT) or as self-administered therapy (SAT) is 
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as effective for preventing TB as other regimens and is more likely to be completed than 
the longer 9 months of INH daily.60,61,62 A four month regimen of rifampicin (4R) has 
been evaluated in adults and children with TB infection (NCT00931736), and found not 
to be inferior to the standard 9-month regimen of isoniazid for the prevention of active 
tuberculosis and, notably, is associated with a higher rate of treatment completion and 
better safety.63 Two ongoing studies are evaluating the effectiveness of preventive 
therapy among people living with HIV (PLHIV): A one month course of daily rifapentine 
and isoniazid (1HP) versus 9H (the A5279 study; NCT01404312) was recently 
completed and preliminary results indicate non-inferiority of the ultrashort regimen when 
applied under pragmatic strategy trial settings;64 and a three arm comparison between 
3HP, 9H and intermittent 3HP is being evaluated among people living with HIV (the 
WHIP3TB study; NCT02980016). The durability of protection achieved from a single six-
month course of INH treatment for TB infection in PLHIV remains uncertain, with some 
trials showing up to seven years of protection,65 while others found significant benefits 
from prolonged courses (36 months) of INH treatment in high-incidence settings as 
compared to the six-month regimen.66 The CORTIS study is evaluating the 
effectiveness of 3HP for high-risk individuals, against surveillance, with the treatment 
decision based upon a blood-based RNA -expression profile (NCT02735590). 
Supervised weekly 3HP is being compared to isoniazid among pregnant and post-
partum women (P2001; NCT02651259). Finally, six weeks of daily, self-administered 
rifapentine alone regimen is being evaluated in a new phase 3 clinical trial conducted by 
the CDC TB Trials Consortium.67  
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Currently, there are limited data on how best to treat contacts of individuals with 
multidrug-resistant (MDR)- and extensively drug-resistant (XDR)-TB. Several drugs or 
combinations of drugs including fluoroquinolones, ethambutol, pyrazinamide and 
ethionamide have been tested in modest sized trials that have not provided adequate 
evidence to impact practice guidelines. Currently, three large, randomized controlled 
trials are underway. Six months of daily levofloxacin is being compared to placebo for 
contacts of individuals with MDR-TB in the VQUIN MDR Trial 
(ACTRN12616000215426, in adults), and the TB CHAMP study (ISRCTN92634082, in 
children under five years). In the PHOENIX MDR-TB Trial, six months of daily 
delamanid will be compared with six months of daily isoniazid for contacts of individuals 
with MDR- or XDR-TB. 
Current treatment studies focus on the use of orally-administered antibiotics for 
which susceptibility is presumed, however, there is interest in evaluating novel, non-
antibiotic based approaches to treating infection and halting progression to disease, as 
well as alternative drug-delivery mechanisms.  The idea of using host-directed therapies 
as adjunctive therapies for TB has gained traction.68 Theoretically, host-directed 
therapies can address the challenges associated with antibiotic resistance, as bacterial 
mutations will be incapable of directly abrogating binding of the drug to a host target. In 
addition, these therapies open a new landscape of ways to harness or alter host 
immunity to attack the pathogen.  A number of host-directed therapies have been 
proposed based on modulation of detrimental inflammation – more classically 
considered in the context of clinically apparent disease – including alterations of 
eicosanoid networks, lipid metabolism, and autophagy, among others.69,70,71  Questions 
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remain about whether these newer host-directed approaches would be effective for 
addressing the spectrum of infection, where the inflammatory response may be different 
from active disease.  Answering these questions is an important first step in determining 
the role of adjunctive host-directed medications or therapeutic vaccines in the 
prevention of progression from infection to disease.5  
There remain a number of challenges in efficiently transforming pre-clinical 
results and clinical observations into specific adjunctive therapies, particularly given the 
heterogeneity in disease presentation and progression. Cell culture, animal models, 
human clinical data and long-term experiments in non-human primates (e.g. 
cynomolgus macaques or rhesus macaques, where infection with M. tuberculosis 
results in similar outcomes as the human infection/disease spectrum) are needed to 
capture the full spectrum of possibilities with adjunctive therapies. Ultimately, novel 
adjunctive therapies will require initial assessment of safety, consideration of potential 
interactions with front-line anti-TB drugs, and knowledge of efficacy in pre-clinical 
models.  
Ensuring that treatment can be delivered is also a critical area of inquiry.  Long-
acting/extended release drug formulations have proved very successful in diverse areas 
of medicine including contraception, psychiatry, and most recently, HIV disease. While 
challenging, application of this technology to TB treatment could have substantial 
impact by improving treatment adherence.  Although the properties of some TB drugs 
make them unsuitable for long-acting formulation, promising candidates have been 
identified through modelling and simulations.72,73,74,75  An efficacious delivery 
mechanism for TB infection, particularly for those co-infected with HIV, would be an 
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important tool to accelerate progress towards TB elimination.  Progress in this area is 
closely linked to the identification of markers associated with disease clearance and 
progression. 
Understanding host-pathogen interactions in the setting of high transmission 
pressure is also an important facet of combatting the disease.  While many of the early 
studies on preventive therapy were undertaken in high-burden settings,8,9,10,11,12 and 
models of disease elimination have underscored the importance of using a 
comprehensive epidemic control approach strategy that includes active case finding, the 
treatment of active disease, and the treatment of infected contacts,76,77,78 research is 
required to better understand how targeted identification of infected individuals in 
“hotspots” and other epidemiological contexts could advance the goal of TB 
elimination.79 
Lastly it must be remembered that most of the studies on the relationship 
between M. tuberculosis and its human host have been conducted in adults.  There are 
an estimated 10 million new pediatric TB infections each year.80  Once infected with M. 
tuberculosis the risk of disease progression is much higher in children especially those 
<5 years of age.81  Because of differences in host immunity between young children and 
older children and adults, this population faces a different series of gaps in diagnostics 
and therapeutics.  Studying TB infection in children—who usually have a defined 
contact and hence defined time since exposure—is a unique “challenge model” to 
examine time-and possibly strain-related infection progression and protection.82 
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Conclusions
TB elimination can only be achieved if the reservoir of infected individuals at high 
risk of progression to disease are identified and treated.  Recent advances in our 
understanding of host-pathogen interactions in TB, coupled with newer approaches for 
diagnosis, predictive biomarkers of risk for progression, and the promise of shorter 
duration treatments, adjunctive therapies and innovative modalities for drug-delivery are 
providing a new horizon for research. For the first time, the collective of these advances 
provide an exciting and viable platform on which to build the next generation of 
interventions for identifying and treating TB infection. 
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Table 1.  Key research areas and questions in diagnostics and therapeutics.  
1.  Defining the spectrum between M. tuberculosis infection and clinically 
apparent disease, and identifying genetic and immunological markers 
associated with progression to disease?
 Where in the host is the M. tuberculosis population during TB infection, are 
there niche tissues, and do different locations and environments affect 
bacterial behavior, host response, and treatment response?
 What is the physiologic and metabolic state of the population of M. 
tuberculosis along the spectrum between infection and clinically evident 
disease, and could this be used to target individuals for treatment?
 Are there host and pathogen genetic markers (“gene signatures”) that define 
these states, what is the interplay between the two?
 Are there host immunological/cellular function responses that define these 
states?
 Are their protein biomarkers that define these states?
 Can any markers be identified that indicate the presence of live M. 
tuberculosis? 
 Can markers of bacterial clearance in response to chemotherapy or 
therapeutic vaccines be identified? 
 Are genetic, immunological and protein biomarkers the same between adults 
and children, and how can differenced between age groups be used to 
better understand the spectrum between TB infection and disease?
 How is progression along the spectrum to disease affected by host and 
pathogen genetic diversity?
 What are the correlates of protection from TB disease?
 How do the above processes differ between young children and older 
children/adults, and what bearing will this have on identification of infection 
in this population?
2.  Optimizing treatment for infection with M. tuberculosis?
 Which drugs and regimens are optimal for treatment of incipient forms of 
TB?
 What are the drug mechanisms of action that could safely shorten duration 
of treatment for TB infection to 4 weeks or less?  
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 Is there a role for host-directed and adjunctive therapy to modulate 
inflammation, lipid metabolism, autophagy, and other cellular networks, to 
disrupt the transition between TB infection and disease?
 How can host-directed and adjunctive therapies be used to reduce the 
duration of treatment for TB infection?
 What anti-TB drugs are amenable to long-acting/extended release 
formulations that will help maintaining more constant antibiotic coverage and 
help with treatment adherence?
 What anti-TB drugs are amenable to alternative treatment delivery 
mechanisms (e.g. drug patches, depo injections)?
 What drugs should we use to treat individuals suspected of being infected 
with multidrug-resistant (MDR) strains of TB?
 What molecular markers, immunological responses and protein biomarkers 
can help define when infection and/or disease has been successfully 
treated? 
 Do children and adults require the same treatments and durations for TB 
infection?
Page 21 of 32  AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
1 World Health Organization. Tuberculosis fact sheet. 2016; 
http://www.who.int/mediacentre/factsheets/fs104/en/, November 2, 2016
2 Jenkins HE, Pagano M, Yuen CM, Becerra MC, Cohen T. The burden of tuberculosis 
disease in children--Authors' reply. Lancet. 2014 Oct 11;384(9951):1343-4. 
doi:10.1016/S0140-6736(14)61811-0. PubMed PMID: 25307837.
3 Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-
estimation using mathematical modelling. PLoS medicine. 2016;13(10):e1002152.
4 Rangaka MX, Cavalcante SC, Marais BJ, et al. Controlling the seedbeds of 
tuberculosis: diagnosis and treatment of tuberculosis infection. The 
Lancet.386(10010):2344-2353.
5  Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ.  
Tuberculosis (Edinb). Latent tuberculosis infection--Revisiting and revising concepts.  
2015 Jul; 95(4):373-84. doi: 0.1016/j.tube.2015.04.003. Epub 2015 May 15.
6  Parekh MJ, Schluger NW.  Treatment of latent tuberculosis infection.  Ther Av Respir 
Dis.  2013 Dec; 7(6): 351-6.  
7 Getahun H, Matteelli A, Chaisson RE, Raviglione M.  Latent Mycobacterium 
tuberculosis infection.  N Engl J Med. 2015 May 28; 372(22): 2127-35.  
8 Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in 
non-HIV infected persons. Cochrane Database Syst Rev. 2000;(2):CD001363. Review. 
PubMed PMID: 10796642.
9 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in 
HIV infected persons. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000171. doi: 
10.1002/14651858.CD000171.pub3. Review. PubMed PMID: 20091503.
10 Kaplan GJ, Fraser RI, Comstock GW. (1972). Tuberculosis in Alaska, 1970: The 
continued decline of the tuberculosis epidemic. American Review of Respiratory 
Disease, Jun;105(6):920-6.
11 Comstock GW, Baum C, Snider DE Jr. (1979). Isoniazid Prophylaxis among Alaskan 
Eskimos: A Final Report of the Bethel Isoniazid Studies. American Review of 
Respiratory Disease, May;119(5):827-30.
12 Ferebee SH. (1970). Controlled chemoprophylaxis trials in tuberculosis. Bibliotheca 
tuberculosea et medicinae thoracalis, 26:28-106.
Page 22 of 32 AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
13 Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VØ, Andersen ÅB. Molecular 
evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of 
latent infection. The Journal of infectious diseases. 2002;185(3):401-404.
14 Barry, C. E., 3rd, Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, 
D., Wilkinson, R. J. & Young, D. 2009. The Spectrum Of Latent Tuberculosis: 
Rethinking The Biology And Intervention Strategies. Nat Rev Microbiol, 7, 845-55.
15 Ernst JD. The Immunological Life Cycle Of Tuberculosis. Nat Rev Immunol. 
2012;12(8):581-91.
16 Scriba, T. J., Penn-Nicholson, A., Shankar, S., Hraha, T., Thompson, E. G., Sterling, 
D., Nemes, E., Darboe, F., Suliman, S., Amon, L. M., Mahomed, H., Erasmus, M., 
Whatney, W., Johnson, J. L., Boom, W. H., Hatherill, M., Valvo, J., De Groote, M. A., 
Ochsner, U. A., Aderem, A., Hanekom, W. A., Zak, D. E. & Other Members Of The, A. 
C. S. C. S. T. 2017. Sequential Inflammatory Processes Define Human Progression 
From M. Tuberculosis Infection To Tuberculosis Disease. Plos Pathog, 13, E1006687.
17 Pai, M. 2010. Spectrum Of Latent Tuberculosis - Existing Tests Cannot Resolve The 
Underlying Phenotypes. Nat Rev Microbiol, 8, 242; Author Reply 242.
18 Nuermberger, E., Bishai, W. R. & Grosset, J. H. 2004. Latent Tuberculosis Infection. 
Semin Respir Crit Care Med, 25, 317-36.
19 Dutta, N. K. & Karakousis, P. C. 2014. Latent Tuberculosis Infection: Myths, Models, 
And Molecular Mechanisms. Microbiol Mol Biol Rev, 78, 343-71.
20 Schraufnagel DE. 2016. "Latent Tuberculosis Infection" Is A Term That Should Go 
Dormant, And The Significance Of Latent Tuberculosis Should Be Rethought. Ann Am 
Thorac Soc, 13, 593-4.
21 Pandey AK, Sassetti CM.  Mycobacterial Persistence Requires The Utilization Of 
Host Cholesterol. 2008. Proc Natl Acad Sci U S A, 105, 4376-80.
22 Munoz-Elias EJ, McKinney JD.  Carbon Metabolism Of Intracellular Bacteria. 2006. 
Cell Microbiol, 8, 10-22.
23 Baek SH, Li AH, Sassetti CM.  Metabolic Regulation Of Mycobacterial Growth And 
Antibiotic Sensitivity. 2011 Plos Biol, 9, E1001065.
24 Boshoff HI, Barry CE 3rd.  Tuberculosis - Metabolism And Respiration In The Absence 
Of Growth. 2005 Nat Rev Microbiol, 3, 70-80.
25 Cunningham-Bussel A, Zhang T, Nathan CF.  Nitrite Produced By Mycobacterium 
Tuberculosis In Human Macrophages In Physiologic Oxygen Impacts Bacterial ATP 
Consumption And Gene Expression. 2013; Proc Natl Acad Sci U S A, 110, E4256-65.
Page 23 of 32  AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
26 Gouzy A, Poquet Y, Neyrolles O.  Nitrogen Metabolism In Mycobacterium 
Tuberculosis Physiology And Virulence. 2014 Nat Rev Microbiol, 12, 729-37.
27 Kesavan AK, Brooks M, Tufariello J, Chan J, Manabe YC.  Tuberculosis Genes 
Expressed During Persistence And Reactivation In The Resistant Rabbit Model. 
2009;Tuberculosis (Edinb), 89, 17-21.
28 Muttucumaru DG, Roberts G, Hinds J, Stabler RA, Parish T.  Gene Expression Profile 
Of Mycobacterium Tuberculosis In A Non-Replicating State. 2004; Tuberculosis (Edinb), 
84, 239-46
29 Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha 
U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry 
CE 3rd.  Tuberculous Granulomas Are Hypoxic In Guinea Pigs, Rabbits, And Nonhuman 
Primates. 2008; Infect Immun, 76, 2333-40.
30 Mortaz E, Adcock IM, Tabarsi P, Masjedi MR, Mansouri D, Velayati AA, Casanova JL, 
Barnes PJ. Interaction Of Pattern Recognition Receptors With Mycobacterium 
Tuberculosis. J Clin Immunol. 2015;35(1):1-10. Doi: 10.1007/S10875-014-0103-7. 
Pubmed PMID: 25312698; PMCID: PMC4306732.
31 Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang 
ND, Chau TT, Vary JC, Hawn TR, Dunstan SJ, Farrar JJ, Thwaites GE, King MC, 
Serhan CN, Ramakrishnan L. Host genotype-specific therapies can optimize the 
inflammatory response to mycobacterial infections. Cell. 2012 Feb 3;148(3):434-46. doi: 
10.1016/j.cell.2011.12.023. PubMed PMID: 22304914; PubMed Central PMCID: 
PMC3433720.
32 Portevin D, Gagneux S, Comas I, Young D. Human macrophage responses to clinical 
isolates from the Mycobacterium tuberculosis complex discriminate between ancient 
and modern lineages. PLoS Pathog. 2011;7(3):e1001307. doi: 
10.1371/journal.ppat.1001307. PubMed PMID: 21408618; PMCID: PMC3048359.
33 Krishnan N, Malaga W, Constant P, Caws M, Tran TH, Salmons J, Nguyen TN, 
Nguyen DB, Daffe M, Young DB, Robertson BD, Guilhot C, Thwaites GE. 
Mycobacterium tuberculosis lineage influences innate immune response and virulence 
and is associated with distinct cell envelope lipid profiles. PLoS One. 2011;6(9):e23870. 
doi: 10.1371/journal.pone.0023870. PubMed PMID: 21931620; PMCID: PMC3169546.
34 Carmona J, Cruz A, Moreira-Teixeira L, Sousa C, Sousa J, Osorio NS, Saraiva AL, 
Svenson S, Kallenius G, Pedrosa J, Rodrigues F, Castro AG, Saraiva M. 
Mycobacterium tuberculosis Strains Are Differentially Recognized by TLRs with an 
Impact on the Immune Response. PLoS One. 2013;8(6):e67277. doi: 
10.1371/journal.pone.0067277. PubMed PMID: 23840651; PMCID: PMC3693941.
Page 24 of 32 AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
35 Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, Thuong NT, Stepniewska K, 
Huyen MN, Bang ND, Loc TH, Gagneux S, van Soolingen D, Kremer K, van der Sande 
M, Small P, Anh PT, Chinh NT, Quy HT, Duyen NT, Tho DQ, Hieu NT, Torok E, Hien 
TT, Dung NH, Nhu NT, Duy PM, van Vinh Chau N, Farrar J. The influence of host and 
bacterial genotype on the development of disseminated disease with Mycobacterium 
tuberculosis. PLoS Pathog. 2008 Mar 28;4(3):e1000034. doi: 
10.1371/journal.ppat.1000034. PubMed PMID: 18369480; PubMed Central PMCID: 
PMC2268004.
36 Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, Weber RP, 
Jonas DE. Screening for Latent Tuberculosis Infection in Adults: An Evidence Review 
for the U.S. Preventive Services Task Force. Evidence Synthesis No. 142. AHRQ 
Publication No. 14-05212EF-1. Rockville, MD: Agency for Healthcare Research and 
Quality; 2016.
37 Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM, 
Rengarajan J. Biomarkers on patient T cells diagnose active tuberculosis and monitor 
treatment response. J Clin Invest. 2015 Sep;125(9):3723. doi: 10.1172/JCI83279. Epub 
2015 Sep 1. PubMed PMID: 26325038; PubMed Central PMCID: PMC4588276.
38 Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed 
H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver 
S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, 
Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, 
Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA; ACS and 
GC6-74 cohort study groups. A blood RNA signature for tuberculosis disease risk: a 
prospective cohort study. Lancet. 2016 Jun 4;387(10035):2312-2322. doi: 
10.1016/S0140-6736(15)01316-1. Epub 2016 Mar 24. PubMed PMID: 27017310; 
PubMed Central PMCID: PMC5392204.
39 Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, 
Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, 
Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. An 
interferon-inducible neutrophil-driven blood transcriptional signature in human 
tuberculosis. Nature. 2010 Aug 19;466(7309):973-7. doi: 10.1038/nature09247. 
PubMed PMID: 20725040; PubMed Central PMCID: PMC3492754. 
40 Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S, Penn-
Nicholson A, Thiel B, Erasmus M, Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley 
K, Downing K, Fisher ML, Valvo J, Parida SK, van der Spuy G, Tromp G, Adetifa IMO, 
Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell H, Ottenhoff THM, Hatherill 
M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SH, Zak DE, Walzl G; and the GC6-
74 and ACS cohort study groups. Four-gene Pan-African Blood Signature Predicts 
Progression to Tuberculosis. Am J Respir Crit Care Med. 2018 Apr 6. doi: 
10.1164/rccm.201711-2340OC. [Epub ahead of print] PubMed PMID: 29624071.
Page 25 of 32  AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
41 Dambrun M, Dechavanne C, Emmanuel A, Aussenac F, Leduc M, Giangrande C, 
Vinh J, Dugoujon JM, Lefranc MP, Guillonneau F, Migot-Nabias F. Human 
Immunoglobulin Heavy Gamma Chain Polymorphisms: Molecular Confirmation Of 
Proteomic Assessment.  Mol Cell Proteomics. 2017 May;16(5):824-839. doi: 
10.1074/mcp.M116.064733. Epub 2017 Mar 6. PubMed PMID: 28265047; PubMed 
Central PMCID: PMC5417824.
42 Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, 
Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, 
Glennie MJ, White AL. Complex Interplay between Epitope Specificity and Isotype 
Dictates the Biological Activity of Anti-human CD40 Antibodies. Cancer Cell. 2018 Apr 
9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22. PubMed 
PMID: 29576376; PubMed Central PMCID: PMC5896247.
43 Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, Abdool 
Karim S, Moore PL, Ackerman ME, Alter G, Morris L. HIV-specific Fc effector function 
early in infection predicts the development of broadly neutralizing antibodies. PLoS 
Pathog. 2018 Apr 9;14(4):e1006987. doi: 10.1371/journal.ppat.1006987. eCollection 
2018 Apr. PubMed PMID: 29630668; PubMed Central PMCID: PMC5908199.
44 Alter G, Dowell KG, Brown EP, Suscovich TJ, Mikhailova A, Mahan AE, Walker BD, 
Nimmerjahn F, Bailey-Kellogg C, Ackerman ME. High-resolution definition of humoral 
immune response correlates of effective immunity against HIV. Mol Syst Biol. 2018 Mar 
26;14(3):e7881. doi: 10.15252/msb.20177881. PubMed PMID: 29581149; PubMed 
Central PMCID: PMC5868198.
45 Kaifu T, Nakamura A. Polymorphisms of immunoglobulin receptors and the effects on 
clinical outcome in cancer immunotherapy and other immune diseases: a general 
review. Int Immunol. 2017 Jul 1;29(7):319-325. doi: 10.1093/intimm/dxx041. Review. 
PubMed PMID: 28910969.
46 Cell. 2016 Oct 6;167(2):433-443.e14. doi: 10.1016/j.cell.2016.08.072. Epub 2016 Sep 
22. A Functional Role for Antibodies in Tuberculosis. Lu LL1, Chung AW2, Rosebrock 
TR3, Ghebremichael M4, Yu WH5, Grace PS4, Schoen MK4, Tafesse F4, Martin C3, 
Leung V3, Mahan AE4, Sips M6, Kumar MP7, Tedesco J4, Robinson H4, Tkachenko 
E4, Draghi M4, Freedberg KJ4, Streeck H8, Suscovich TJ4, Lauffenburger DA7, 
Restrepo BI9, Day C10, Fortune SM11, Alter G12.
47 Du Plessis N, Jacobs R, Gutschmidt A, Fang Z, van Helden PD, Lutz MB, Hesseling 
AC, Walzl G. Phenotypically resembling myeloid derived suppressor cells are increased 
in children with HIV and exposed/infected with Mycobacterium tuberculosis. Eur J 
Immunol. 2017. 47(1):107-118. doi: 10.1002/eji.201646658. PMID: 27861788
48 Du Plessis N, Loebenberg L, Kriel M, von Groote-Bidlingmaier F, Ribechini E, Loxton 
AG, van Helden PD, Lutz MB, Walzl G. Increased Frequency of Myeloid Derived 
Page 26 of 32 AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
Suppressor Cells during Active Tuberculosis and Following Recent Mycobacterium 
tuberculosis Infection Suppresses T Cell Function. Am J Respir Crit Care Med. 2013; 
188(6):724-32. doi: 10.1164/rccm.201302-0249OC. PMID: 23885784
49 Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM, 
Rengarajan J. Biomarkers on patient T cells diagnose active tuberculosis and monitor 
treatment response. J Clin Invest. 2015 Sep;125(9):3723. doi: 10.1172/JCI83279. Epub 
2015 Sep 1. PubMed PMID: 26325038; PubMed Central PMCID: PMC4588276.
50 Wergeland I, Assmus J, Dyrhol-Riise AM. Cytokine Patterns in Tuberculosis Infection; 
IL-1ra, IL-2 and IP-10 Differentiate Borderline QuantiFERON-TB Samples from 
Uninfected Controls. van Zyl-Smit R, ed. PLoS ONE. 2016;11(9):e0163848. 
doi:10.1371/journal.pone.0163848.
51 Rangaka MZ, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, 
Fielding K, Wilkinson RJ, Pai M.  Predictive value of interferon-γ release assays for 
incident active tuberculosis: a systematic review and meta-analysis.  Lancet Infect Dis. 
2012 Jan; 12(1):45-55.  
52 Pan L, Wei N, Jia H, Gao M, Chen X, Wei R, Sun Q, Gu S, Du B, Xing A, Zhang Z. 
Genome-wide transcriptional profiling identifies potential signatures in discriminating 
active tuberculosis from latent infection. Oncotarget. 2017 Dec 4;8(68):112907-112916. 
doi: 10.18632/oncotarget.22889. eCollection 2017 Dec 22. PubMed PMID: 29348876; 
PubMed Central PMCID: PMC5762561.
53 Thompson EG, Shankar S, Gideon HP, Braun J, Valvo J, Skinner JA, Aderem A, 
Flynn JL, Lin PL, Zak DE. Prospective Discrimination of Controllers From Progressors 
Early After Low-Dose Mycobacterium tuberculosis Infection of Cynomolgus Macaques 
using Blood RNA Signatures. J Infect Dis. 2018 Mar 28; 217(8):1318-1322. doi: 
10.1093/infdis/jiy006. PubMed PMID: 29325117.
54 Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp 
G, Tabb DL, Alland D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, 
Walzl G, Zak DE; Catalysis TB–Biomarker Consortium. Host blood RNA signatures 
predict the outcome of tuberculosis treatment. Tuberculosis (Edinb). 2017 Dec;107:48-
58. doi: 10.1016/j.tube.2017.08.004. Epub 2017 Aug 12. PubMed PMID: 29050771; 
PubMed Central PMCID: PMC5658513.
55 Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, 
Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, 
Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. An 
interferon-inducible neutrophil-driven blood transcriptional signature in human 
tuberculosis. Nature. 2010 Aug 19;466(7309):973-7. doi: 10.1038/nature09247. 
PubMed PMID: 20725040; PubMed Central PMCID: PMC3492754. 
Page 27 of 32  AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
56 Mehaffy C, Dobos KM, Nahid P, Kruh-Garcia NA. Clin Proteomics. 2017 Jun 5;14:21. 
doi: 10.1186/s12014-017-9156-y. eCollection 2017. PMID: 28592925 
57 Kruh-Garcia NA, Wolfe LM, Dobos KM.  Deciphering the role 
of exosomes in tuberculosis. Tuberculosis (Edinb). 2015 Jan;95(1):26-30.
58 Nemes E, Rozot V, Geldenhuys H, Bilek N, Mabwe S, Abrahams D, Makhethe L, 
Erasmus M, Keyser A, Toefy A, Cloete Y, Ratangee F, Blauenfeldt T, Ruhwald M, Walzl 
G, Smith B, Loxton AG, Hanekom WA, Andrews JR, Lempicki MD, Ellis R, Ginsberg 
AM, Hatherill M, Scriba TJ; C-040-404 Study Team and the Adolescent Cohort Study 
Team.  Optimization and Interpretation of Serial QuantiFERON Testing to Measure 
Acquisition of Mycobacterium tuberculosis Infection.  Am J Respir Crit Care Med. 2017 
Sep 1;196(5):638-648. doi: 10.1164/rccm.201704-0817OC.
59 Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, Ran L, van 
Baarle D, Maertzdorf J, Howe R, Mayanja-Kizza H, Boom WH, Thiel BA, Crampin AC, 
Hanekom W, Ota MO, Dockrell H, Walzl G, Kaufmann SH, Ottenhoff TH; GCGH 
Biomarkers for TB consortium. Differential gene expression of activating Fcγ receptor 
classifies active tuberculosis regardless of human immunodeficiency virus status or 
ethnicity. Clin Microbiol Infect. 2014 Apr;20(4):O230-8. doi: 10.1111/1469-0691.12383. 
Epub 2013 Nov 11. PubMed PMID: 24205913.
60 Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, 
Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde 
MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB 
Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. 
N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.  PubMed 
PMID: 22150035.
61  Martinson NA, Barnes GL, Moulton LH, Msandiwa R, et al.  New Regimens to 
Prevent Tuberculosis in Adults with HIV infection.  N Engl J Med 2011; 365:11-20.  
62  Belknap R, Holland D, Feng PJ, Millet JP, et al.  Self-administered Versus Directly 
Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis 
Infection: A randomized Trial.  Ann Intern Med. 2017 Nov 21; 167(10):689-697.
63  Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, 
Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, 
Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, 
Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti 
A.  Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in 
Adults.  N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283.
64 Swindells et al. CROI 2018, Abstract 37LB. One Month of Rifapentine/Isoniazid to 
Prevent TB in People with HIV: BRIEF-TB/A5279.
Page 28 of 32 AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
65  Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, Durovni 
B, Chaisson RE.  Long-term protection from isoniazid preventive therapy 
for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the 
TB/HIV in Rio (THRio) study. Clin Infect Dis. 2015 Feb 15;60(4):639-45. doi: 
10.1093/cid/ciu849. Epub 2014 Nov 2.
66 Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, Mosimaneotsile 
B, Motsamai OI, Bozeman L, Davis MK, Talbot EA, Moeti TL, Moffat HJ, Kilmarx 
PH, Castro KG, Wells CD.  6-month versus 36-month isoniazid preventive treatment for 
tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, 
placebo-controlled trial.  Lancet. 2011 May 7;377(9777):1588-98. doi: 10.1016/S0140-
6736(11)60204-3. Epub 2011 Apr 12.
67  Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily 
for LTBI (ASTERoiD)”: NCT03474029
68  Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, 
Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.  Tuberculosis: 
progress and advances in development of new drugs, treatment regimens, and host-
directed therapies.  Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-
3099(18)30110-5. Epub 2018 Mar 23. Review. Erratum in: Lancet Infect Dis. 2018 Apr 
27;:
69 Zumla A, Rao M, Parida SK, Keshavjee S, Cassell G, Wallis R, Axelsson-Robertsson 
R, Doherty M, Andersson J, Maeurer M. Inflammation and tuberculosis: host-directed 
therapies. J Intern Med. 2015 Apr;277(4):373-87. doi 10.1111/joim.12256. Epub 2014 
May 19. Review. PubMed PMID: 24717092.
70 Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI, Maeurer M. 
Progress in tuberculosis vaccine development and host-directed therapies—a state of 
the art review. Lancet Respir Med. 2014 Apr;2(4):301-20. doi:10.1016/S2213-
2600(14)70033-5. Epub 2014 Mar 24. Review. PubMed PMID: 24717627.
71 Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, 
Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A. Tuberculosis--
advances in development of new drugs, treatment regimens, host-directed therapies, 
and biomarkers. Lancet Infect Dis. 2016 Apr;16(4):e34-46. doi: 10.1016/S1473-
3099(16)00070-0. Review. PubMed PMID:27036358.
72  Rajoli RKR, Podany AT, Moss DM, Swindells S, Flexner C, Owen A, Siccardi M.  
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof 
of concept study.  Int J Tuberc Lung Dis. 2018 Aug 1;22(8):937-944. doi: 
10.5588/ijtld.17.0515.  PMID: 29991405
Page 29 of 32  AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
73 Swindells S1, Siccardi M2, Barrett SE3, Olsen DB4, Grobler JA4, Podany 
AT1, Nuermberger E5, Kim P6, Barry CE7, Owen A2, Hazuda D4, Flexner C5.Long-
acting formulations for the treatment of latent tuberculous infection: opportunities and 
challenges.  Int J Tuberc Lung Dis. 2018 Feb 1;22(2):125-132. doi: 
10.5588/ijtld.17.0486.
74  Kailasam S, Wise DL, Gangadharam PR.  Bioavailability and chemotherapeutic 
activity of clofazimine against Mycobacterium avium complex infections in beige mice 
following a single implant of a biodegradable polymer.  J Antimicrob Chemother. 1994 
Feb;33(2):273-9.  
75  Gangadharam PR, Kailasam S, Srinivasan S, Wise DL.  Experimental chemotherapy 
of tuberculosis using single dose treatment with isoniazid in biodegradable polymers.  J 
Antimicrob Chemother. 1994 Feb;33(2):265-71.
76   Dye C, Glaziou P, Floyd K, Raviglione M.  Prospects for tuberculosis elimination.
Annu Rev Public Health. 2013;34:271-86. doi: 10.1146/annurev-publhealth-031912-
114431. Epub 2012 Dec 14. Review.  PMID: 23244049
77   Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, Dye C, 
Halloran ME.Epidemiological benefits of more-effective tuberculosis vaccines, drugs, 
and diagnostics.  Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13980-5. doi: 
10.1073/pnas.0901720106. Epub 2009 Aug 3.  PMID: 19666590
78  Reid A, Grant AD, White RG, Dye C, Vynnycky E, Fielding K, Churchyard G, Pillay Y.  
Accelerating progress towards tuberculosis elimination: the need for combination 
treatment and prevention.  Int J Tuberc Lung Dis. 2015 Jan;19(1):5-9. doi: 
10.5588/ijtld.14.0078.  PMID: 25519784
79   Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, 
Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, 
Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al 
Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, 
Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle 
UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, 
Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, 
Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo 
Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu 
G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, 
Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC. Towards tuberculosis elimination: 
an action framework for low-incidence countries.  Eur Respir J. 2015 Apr;45(4):928-52. 
doi: 10.1183/09031936.00214014. Review. PMID:  25792630
Page 30 of 32 AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
80 Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 
high-burden countries: a mathematical modelling study. The Lancet Global health. 
2014;2(8):e453-9
81 Marais, B. J., et al. (2004). "The natural history of childhood intra-thoracic 
tuberculosis: a critical review of literature from the pre-chemotherapy era." Int J Tuberc 
Lung Dis 8(4): 392-402.
82 Basu Roy, R., et al. (2012). "Current understanding of the immune response to 
tuberculosis in children." Curr Opin Infect Dis 25(3): 250-257.
Page 31 of 32  AJRCCM Articles in Press. Published on 18-October-2018 as 10.1164/rccm.201806-1053PP 
 Copyright © 2018 by the American Thoracic Society 
Disease 
Biomarker + 
TST + 
Active TB Uninfected Host 
Transmission 
Active TB 
Possible establishment of 
the spectrum of latent TB  
Treatment 
Infected 
TST/IGRA positive 
Infected 
TST/IGRA positive 
Evolving biomarker signature 
for progression 
Infected 
TST/IGRA positive 
Radiographical/microbiological 
evidence of early disease –no 
symptoms 
Spectrum of TB infection prior to the diagnosis of active TB 
Eradication  of 
all bacteria 
Outstanding questions  
on Bacterial physiology 
The Influence of Immune 
Responses 
New Diagnostic 
Approaches 
The role of 
HDTs 
Possible Therapeutic 
Options 
• Location/sampling? 
• Metabolic alterations 
      (Cholesterol/lipids) 
• Respiration (alternate 
electron acceptors) 
• Replication competence? 
• Drug vulnerability? 
• Exsosomes 
• Antibodies 
• Biomarkers 
• Modulators of 
inflammation? 
• Lipid 
metabolism? 
• Autophagy? 
• 9H – current 
• 4R 
• 1HP 
• 3HP 
• Levofloxacin 
• 6H(+delaminid) 
• Innate immunity 
• LTA4H 
• TLR2 
Figure 1. Spectrum of clinical states that comprise asymptomatic TB infection. Shown are the various 
manifestations of infection with Mycobacterium tuberculosis, prior to the diagnosis of active TB. The spectrum of 
TB infected states, which were previously all characterized as latent TB infection, represents a diversity of 
outcomes upon exposure to infectious particles. This appreciation of clinical complexity has been largely driven 
by the development of biomarkers to monitor risk of disease progression and refined imaging techniques. Text 
below the graphic details areas of investigation necessary to better characterize the latency spectrum including 
study of bacterial physiology, novel diagnostics, HDTs, new therapeutic options and host immunity. The ultimate 
goal of further understanding the spectrum of TB infection is to develop interventions that prevent progression 
to active TB disease. H-isoniazid, R-rifampin, P – rifapentine. 
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